Siemens Healthineers (OTCMKTS:SMMNY) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Siemens Healthineers (OTCMKTS:SMMNY) from a strong sell rating to a hold rating in a research note released on Thursday,Zacks.com reports.

Siemens Healthineers Stock Performance

SMMNY opened at $22.81 on Thursday. The stock’s fifty day moving average is $20.20 and its two-hundred day moving average is $21.66. Siemens Healthineers has a 52 week low of $19.20 and a 52 week high of $28.92.

Siemens Healthineers (OTCMKTS:SMMNY) last issued its earnings results on Thursday, May 7th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.02. The firm had revenue of $6.68 billion for the quarter, compared to the consensus estimate of $6.96 billion.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.